GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
10 août 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via NewMediaWire — GeoVax Labs, Inc....
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
09 août 2023 16h00 HE
|
GeoVax, Inc.
Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to Host Conference Call and Webcast...
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
26 juil. 2023 09h00 HE
|
GeoVax, Inc.
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Issuance of Ebola Vaccine Patent
24 juil. 2023 09h00 HE
|
GeoVax, Inc.
Addressing Multiple Strains of Ebolavirus ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
20 juil. 2023 09h00 HE
|
GeoVax, Inc.
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
10 juil. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
28 juin 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
27 juin 2023 10h15 HE
|
GeoVax, Inc.
Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
31 mai 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming Industry Meetings
25 mai 2023 09h00 HE
|
GeoVax, Inc.
Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...